Document Detail

Effects of verapamil and ibutilide on atrial fibrillation and postfibrillation atrial refractoriness.
MedLine Citation:
PMID:  11900290     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Early recurrence of atrial fibrillation (AF) after cardioversion may be related to shortening of the atrial effective refractory period (ERP). This study compared the effects of verapamil and ibutilide on AF cycle length (AFCL), atrial ERP, and susceptibility to recurrent AF. METHODS AND RESULTS: In 33 adults, the atrial ERP was measured at basic drive CLs of 350 and 500 msec before and after a brief episode of pacing-induced AF. During AF, verapamil, ibutilide, or saline was infused in 11 patients each. Shortening of the post-AF atrial ERP was attenuated by verapamil and prevented by ibutilide. AFCL shortened by 32+/-21 msec in the verapamil group (P < 0.01), prolonged by 44+/-14 msec in the ibutilide group (P < 0.001), and did not change in the control group. AF converted to sinus rhythm within 10 minutes less often after verapamil (0%) than after ibutilide (82%) or than in the control group (73%). Post-AF, AF lasting > 10 minutes was induced more often in the verapamil group than in the ibutilide group (26% vs 0%; P = 0.01). Another 10 patients received verapamil or ibutilide in the absence of AF. Atrial ERP was unchanged after verapamil and prolonged after ibutilide. CONCLUSION: Verapamil shortens AFCL and impedes the conversion of induced AF, whereas ibutilide prolongs AFCL and does not impede the early conversion of induced AF. Ibutilide is more effective than verapamil in preventing pos
Christian Sticherling; William Hsu; Hiroshi Tada; Anton C Bares; Hakan Oral; Frank Pelosi; Bradley P Knight; S Adam Strickberger; Fred Morady
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of cardiovascular electrophysiology     Volume:  13     ISSN:  1045-3873     ISO Abbreviation:  J. Cardiovasc. Electrophysiol.     Publication Date:  2002 Feb 
Date Detail:
Created Date:  2002-03-19     Completed Date:  2002-10-02     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9010756     Medline TA:  J Cardiovasc Electrophysiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  151-7     Citation Subset:  IM    
Department of Internal Medicine II, Free University of Berlin, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Arrhythmia Agents / therapeutic use*
Atrial Fibrillation / drug therapy*,  etiology,  physiopathology
Cardiac Pacing, Artificial / adverse effects
Chi-Square Distribution
Heart Atria / drug effects,  physiopathology
Refractory Period, Electrophysiological / drug effects
Sulfonamides / therapeutic use*
Treatment Outcome
Verapamil / therapeutic use*
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 0/Sulfonamides; 130350-52-6/ibutilide; 52-53-9/Verapamil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Analysis of troponin I levels after spontaneous implantable cardioverter defibrillator shocks.
Next Document:  Atrial morphology in hearts with congenitally corrected transposition of the great arteries: implica...